RE: AVS and Laparoscopic Adrenalectomy Cost

[Guest guest]

I have no idea. Mine was done for free at our National Institutes of Health by doctors in the Uniformed Public Health Service, with case management by research fellows, who are doctors who have completed their residencies but who have not yet started private practice.

Bindner

Web Directory (links to my sites and blogs):

http://www.geocities.com/mikeybdc/index.html

http://mikeybdc.blogspot.com

From: <bryanfjohnson@...>Subject: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Wednesday, December 30, 2009, 4:42 PM

Hi,What is the typical cost for AVS and the Laparoscopic Adrenalectomy?I am considering doing the operation in US.

[Guest guest]

You should call the Mayo Clinic in Rochester, MN and ask.  Then, let us know what they said.  Where are you? 

My congressman, Polis, owns part of a medical tourism

company.  He has anticipated that many

Americans will go offshore when choice diminishes here.  You might contact that company.  http://bridgehealthinternational.com/

Things are a little confused right now.  Services tend to be less expensive if you

have insurance unless the doctor chooses to charge a reasonable price for those

who pay cash.  I just had a bunch of lab

tests done.  Labcorp billed $1,700.  By the time my insurance (Blue Cross)

considered it, only a little over $100 was allowed so that is what I was

required to pay.

Val

---

On Wed, 12/30/09, <bryanfjohnson@...> wrote:

What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

I am considering doing the operation in US.

[Guest guest]

One got billed nearly $18000 for AVS at Mich so u want to be sure it is preapproved. Tiped sad Send form miiPhone ;-)May your pressure be low!CE Grim MDSpecializing in DifficultHypertensionOn Dec 30, 2009, at 1:42 PM, <bryanfjohnson@...> wrote:

Hi,

What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

I am considering doing the operation in US.

[Guest guest]

I live in Jamaica. Mike does the NIH

take people outside of the US? Could you give me a link

>

> > Hi,

> >

> > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> >

> > I am considering doing the operation in US.

> >

> >

>

[Guest guest]

I was just looking at my insurance to see what they billed my insurance it is

was around $20,000 for everything. That is before any adjustments and that is

not what I have to pay for my insurance. so wells ee.

>

> What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

>

> I am considering doing the operation in US.

>

[Guest guest]

I'm sorry, that was only for the AVS. I had surgery not laparoscopic and haven't

seen that bill yet. We had dinner with some people from England the other day

nad they have universal health care and he said that you pay monthly into an

insurance, like $60 a month and I wouldn't of had to pay for an extra penny for

the surgery. They just pay medication then on top of that they have 10 months

paid maternity leave. Told my husband need to move there! ha

> >

> > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> >

> > I am considering doing the operation in US.

> >

>

[Guest guest]

$4,000 to $5000 at Mayo Clinic in Rochester. About $12,000 with all other tests they do including doctor's charges. ($12,000 includes the $4000-$5000).Each hospital and doctor has their own charges and thus the charges varies according to the doctors.

On Wed, Dec 30, 2009 at 1:42 PM, <bryanfjohnson@...> wrote:

 

Hi,

What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

I am considering doing the operation in US.

[Guest guest]

Or get the Obama program right.CE Grim MDOn Dec 30, 2009, at 10:15 PM, Rosie wrote:I'm sorry, that was only for the AVS. I had surgery not laparoscopic and haven't seen that bill yet. We had dinner with some people from England the other day nad they have universal health care and he said that you pay monthly into an insurance, like $60 a month and I wouldn't of had to pay for an extra penny for the surgery. They just pay medication then on top of that they have 10 months paid maternity leave. Told my husband need to move there! ha> > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > I am considering doing the operation in US.> >>

[Guest guest]

Amen to that!!! I hope we can do it right or a lot of people are going to

suffer!

> > > >

> > > > What is the typical cost for AVS and the Laparoscopic

> > Adrenalectomy?

> > > >

> > > > I am considering doing the operation in US.

> > > >

> > >

> >

> >

> >

>

[Guest guest]

Does the $12,000 cover both operation and without insurance since I am from

Jamaica (Caribbean)

>

> >

> >

> > Hi,

> >

> > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> >

> > I am considering doing the operation in US.

> >

> >

> >

>

[Guest guest]

Clinical Center Study 00-CH-0180 is actively recruiting participants. If you are

interested in participating in this study, we would like to obtain some

additional information. Please call us toll free at 1-800-366-5165 (TTY

1-866-411-1010). If call volumes are high and you choose to leave a voice

message, please include a telephone number where you can be reached between the

hours of 8:00AM -8:00PM EST Monday through Friday.

> >

> > > Hi,

> > >

> > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> > >

> > > I am considering doing the operation in US.

> > >

> > >

> >

>

[Guest guest]

http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2000-CH-0180.html

> > >

> > > > Hi,

> > > >

> > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> > > >

> > > > I am considering doing the operation in US.

> > > >

> > > >

> > >

> >

>

[Guest guest]

Protocol Number: 00-CH-0180

Title: Endocrine Studies in Health and Disease

Number: 00-CH-0180

Summary: This study will evaluate healthy normal volunteers and patients with a variety of endocrine disorders to 1) learn more about conditions that affect the endocrine glands (glands that secrete hormones) and 2) train physicians in endocrinology.

Patients with endocrine-related conditions and healthy volunteers of all ages may be eligible for this study.

All participants will have a physical examination medical and history. They may be required to provide blood, saliva or urine samples and undergo ultrasound (using sound waves) or magnetic resonance (using a magnetic field) imaging to visualize internal body structures.

Some healthy adult volunteers will have hormone-stimulating tests to assess endocrine function. These tests measure blood hormone levels before and after injection of a synthetic form of a hormone. A device called a heparin lock, through which the hormone is injected and the blood samples are collected, is placed in a vein in the arm or hand. Blood samples are drawn before the hormone is injected and at various intervals after the injection to measure levels of the hormone. These tests, which last from 1 to 3 hours, may include the following:

1. CRH stimulation test-corticotropin-releasing hormone is given to test pituitary and adrenal gland function

2. ACTH stimulation test-adrenocorticotrophic hormone is given to test adrenal gland function

3. LHRH stimulation test-luteinizing hormone-releasing hormone is given to test pituitary gland function

4. TRH stimulation test-thyroid-releasing hormone is given to test pituitary and thyroid gland function

5. GHRH stimulation test-growth hormone releasing hormone is given to measure growth hormone levels.

An oral glucose tolerance test, which is similar to the stimulation tests, may also be done to measure blood glucose (sugar) and insulin levels after drinking a sugary liquid.

Healthy volunteers and patients with a hereditary endocrine disorder and their family members may also be asked to provide a blood sample for genetic studies of inherited endocrine disorders. Patients with endocrine-related disorders may be offered medical or surgical treatment for their disorder.

AcAccess http://turners.nichd.nih.gov/ for additional study publications.

Sponsoring Institute:

National Institute of Child Health and Human Development (NICHD)

Recruitment Detail

Type: Participants currently recruited/enrolled Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria:

INCLUSION CRITERIA

Healthy subjects and patients with endocrine-related conditions of all ages are eligible for this protocol. The actual selection of patients most appropriate for clinical training needs will be made by protocol investigators.

Subjects with disabilities are not formally excluded from the study unless the disability would specifically prevent participation. If a subject with cognitive impairment wishes to participate, there must be available a family member or other qualified individual holding a durable power of attorney who is able to guide the impaired subject's participation and be an advocate for their interests. This participation is limited to the non-research, clinical training arm of the study.

Special Instructions:

This study is not currently recruiting normal volunteers at this time. However, normal volunteers will be recruited in the future for specific studies, each having specific inclusion criteria.

Keywords:

Evaluation Endocrinology Hormones Metabolism Teaching

Recruitment Keyword(s):

Endocrine Disorder

Condition(s):

Endocrine Diseases

Investigational Drug(s):

None

Investigational Device(s):

None

Intervention(s):

None

Supporting Site:

National Institute of Child Health and Human Development

Contact(s): Patient Recruitment and Public Liaison OfficeBuilding 6110 Cloister CourtBethesda, land 20892-4754Toll Free: 1-800-411-1222TTY: 301-594-9774 (local),1-866-411-1010 (toll free)Fax: 301-480-9793 Electronic Mail:prpl@...

Citation(s): Not Provided

If you have:

Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC. Technical questions regarding the Clinical Center web site, please contact the Department of Clinical Research Informatics, CC.

Search The Studies | Help | Questions |Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, land 20892. Last update: 12/31/2009

> > > > > > > > > Hi,> > > > >> > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > >> > > > > I am considering doing the operation in US.> > > > >> > > > >> > > >> > >> >>

[Guest guest]

Thanks Francis.

I don't see AVS on the list of things done though.

Base on where I'm at, I need to do an AVS as further confirmation.

> > > >

> > > > > Hi,

> > > > >

> > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> > > > >

> > > > > I am considering doing the operation in US.

> > > > >

> > > > >

> > > >

> > >

> >

>

[Guest guest]

The Endo fellows don't do the procedure - they arrange for it from Dr. Chaing of their interventional radiology dept. Then, if surgery is indicated, Dr. Kebowbow will do the surgery. At your option, you can donate a piece of your tumor to his research.

I was under this trial. It is free for you (except for your transportation costs and any sick time use). You also need to buy your own Verapamil, Hydralazine and Terasozin to control your BP in the interim (or get a scrip and have someone donate their old supply, which is illegal and probably unsafe - however they gave me a 90 day supply which I will never use after discharge).

Call them already.

Bindner

Web Directory (links to my sites and blogs):

http://www.geocities.com/mikeybdc/index.html

http://mikeybdc.blogspot.com

From: <bryanfjohnson@...>Subject: Re: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Thursday, December 31, 2009, 12:02 PM

Thanks Francis.I don't see AVS on the list of things done though.Base on where I'm at, I need to do an AVS as further confirmation.> > > > > > > > > Hi,> > > > >> > > > > What is the

typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > >> > > > > I am considering doing the operation in US.> > > > >> > > > >> > > >> > >> >>

[Guest guest]

Will depend on where you go. I would go to Dr. Forrester's group down there and ask them. Or do you not have state insurance in jJamaica? If not why not. Would have thought you would have followed the English model.CE Grim MDOn Dec 31, 2009, at 5:25 AM, wrote:Does the $12,000 cover both operation and without insurance since I am from Jamaica (Caribbean)> > >> >> > Hi,> >> > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> >> > I am considering doing the operation in US.> >> > > >>

[Guest guest]

a nother study

Skip to Main Content

Home Search Study Topics Glossary

Full Text View

Tabular View

No Study Results Posted

Related Studies

Study of Adrenal Gland Tumors

This study is currently recruiting participants.

Verified by National Institutes of Health Clinical Center (CC), March 2009

First Received: June 28, 2000 Last Updated: November 25, 2009 History of Changes

Sponsor:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Information provided by:

National Institutes of Health Clinical Center (CC)

ClinicalTrials.gov Identifier:

NCT00005927

Purpose

The adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones. It is not known what causes these tumors or why some secrete hormones and others do not. Some of the tumors are benign and confined to the adrenal gland, and others are malignant (cancerous), and can spread to other parts of the body. This study will investigate how adrenal gland tumors develop, why some secrete steroid hormones and others do not, and why some are benign and others malignant.

Patients between 3 and 70 years old with a known or suspected adrenal gland tumor may be eligible for this study. Participants will be hospitalized for 7 to 10 days for various tests and procedures that may include the following:

Medical history and physical examination, including body measurements, as appropriate. Children and adolescents will have Tanner staging, including examination of the genitals, to determine the extent of sexual maturity.

24-hour urine collection to measure hormones in the urine.

Imaging studies, including magnetic resonance imaging (MRI) of the brain, computed tomography (CT) and other X-ray studies.

Blood tests to see if the tumor secretes hormones in response to specific stimuli, including exercise, food, and various hormones. The hormones are given through an intravenous catheter, or IV-a thin plastic tube inserted into an arm vein. After the stimulus, blood is drawn through the same IV every 30 minutes for up to 3 hours to measure hormone levels. Based on the results of these tests, some patients may have additional blood tests to check hormone response to special foods, an IV salt solution, or other hormones or drugs given either IV or by mouth (in pill form).

Photographs to document the effects on the body of abnormal hormone secretion from the adrenal tumor.

Small samples of blood and tumor tissue for research and DNA (genetic) analysis.

A discussion of treatment options will be based on the results of tests. If surgery to remove the tumor is recommended, the procedure can be done at NIH under this study protocol. If a malignant tumor is found that cannot be treated surgically, chemotherapy or radiation therapy may be recommended. These options are not offered under this protocol, but may be available under a different NIH study (for example, at the National Cancer Institute). Referrals will be made at the patient's request.

Patients who had surgery may be followed at the NIH outpatient clinic for 1 year after surgery. Patients with certain types of tumors may continue to be followed at NIH once a year for up to 5 years.

A registry of study participants will be created to keep records and correlate medical histories with tissues kept at NIH. The registry will also be used to inform participants of research studies they may be interested in. No individuals or organizations outside of NIH will have access to the registry.

Condition

Adrenal Gland Neoplasm

Study Type:

Observational

Official Title:

Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue

Resource links provided by NLM:

Genetics Home Reference related topics: Help Me Understand Genetics

MedlinePlus related topics: Adrenal Gland Cancer Cancer Surgery

Drug Information available for: Epinephrine bitartrate Epinephrine

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:

2000

Study Start Date:

June 2000Detailed Description:

The adrenal glands are the major source in the body of the steroid hormones. In normal physiology, the pituitary hormone ACTH regulates the secretion of glucocorticoids, while the secretion of mineralocorticoids is controlled by the renin-angiotensin system. In addition to these two steroids, the adrenal gland secretes lesser amounts of intermediate metabolites of these steroids, as well as the sex-steroids DHEA, DHEAS, androstenedione, testosterone, estrogen, and estrone. Dysregulated secretion of any of these hormones can be caused by sporadic adrenocortical adenomas or carcinomas, with the development of specific clinical syndromes depending on the identity of the hormones secreted. Similar clinical phenomena can also occur in the setting of a primary, bilateral hyperplasia of the adrenal cortex. In at least a subset of cortisol-producing adrenocortical neoplasms, the presence of ectopic or abnormal receptors has been described, resulting in the regulation of cortisol by non-physiologic stimuli. The present study will serve as a mechanism to investigate individuals with steroid hormone-secreting adrenocortical tumors of all types for the purpose of identifying hereditary, congenital, or acquired defects leading not only to hormone oversecretion, but also to tumor formation. The first goal of the study will be to examine the prevalence of ectopic receptor expression in hormone secreting adrenocortical tumors. This aim will aid in the understanding of the ontogeny of these tumors, as well as lead to the development of novel therapeutic strategies (e.g., receptor antagonists) to control hormone oversecretion. The second goal of the study will be to perform a comparative analysis of the expression of large sets of genes using the emerging technology of gene array/gene chip analysis. This study will generate important diagnostic information about the malignant potential of adrenocortical neoplasms, information which at present can only be obtained through follow-up of patients and retrospective analysis. This information may help to identify patients who would benefit from more aggressive intervention strategies. Thirdly, this study will also provide for the establishment of a bank of tissues of varying malignant potential from the adrenal cortex, which may serve in the future as an experimental resource to test new diagnostic and therapeutic methods.

Eligibility

Ages Eligible for Study:

3 Years to 70 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

INCLUSION CRITERIA:

Patients are adults or children with evidence for the existence of a tumor of the adrenal glands, as indicated by previously obtained imaging studies and/or biochemical investigation of hormonal secretion.

Patients must be willing to return to the NIH for follow-up evaluation.

Patients may withdraw from the study at any time.

For family members studied for linkage analysis, the following criteria must be met:

These individuals can be of any age. Each must be a member of a kindred suspected of having an inherited form of adrenal neoplasia, as evidenced by results of a patient studied under above eligibility criteria.

EXCLUSION CRITERIA:

Children less than 3 years old will be excluded.

Individuals over the age of 70 years of age will be excluded.

Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing or who have unacceptably high risk for surgical morbidity and mortality will be excluded.

Individuals found to have a known inherited syndrome as the cause for hormone oversecretion will be excluded.

Specific examples of syndromes to may be excluded from this protocol include individuals with Carney Complex, McCune-Albright syndrome, and MEN-1.

Individuals with a diagnosis of glucocorticoid-remediable aldosteronism (GRA) are excluded from participation in this protocol.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005927

Contacts

Contact: Patient Recruitment and Public Liaison Office

(800) 411-1222

prpl@...

Contact: TTY

1-866-411-1010

Locations

United States, land

National Institutes of Health Clinical Center, 9000 Rockville Pike

Recruiting

Bethesda, land, United States, 20892

Sponsors and Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

More Information Additional Information: NIH Clinical Center Detailed Web Page Publications:

Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1999 Dec;84(12):4341-4. Review. No abstract available.

Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm. 1999;57:177-216. Review.

Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998 Sep;83(9):3214-8.

Study ID Numbers:

000160, 00-CH-0160

Study First Received:

June 28, 2000

Last Updated:

November 25, 2009

ClinicalTrials.gov Identifier:

NCT00005927 History of Changes

Health Authority:

United States: Federal GovernmentKeywords provided by National Institutes of Health Clinical Center (CC):

Adrenal AdenomaAdrenal CancerMacronodular AdrenalsEctopic ReceptorsGene ProfilingAdrenocortical Carcinoma

Cushing SyndromeVirilizing Adrenal TumorFeminizing Adrenal TumorMassive Macronodular Adrenocortical DiseaseAdrenal Gland TumorAdditional relevant MeSH terms:

NeoplasmsNeoplasms by SiteAdrenal Gland Neoplasms

Endocrine System DiseasesAdrenal Gland DiseasesEndocrine Gland NeoplasmsClinicalTrials.gov processed this record on December 30, 2009

Back to top of Main Content

Contact Help DeskLister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services,USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act Links to all studies - primarily for crawlers > > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>

[Guest guest]

Thanks Mike.

Just called. They need my Endo to give the Study Coordinator a call.

> > > > >

> > > > > > Hi,

> > > > > >

> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?

> > > > > >

> > > > > > I am considering doing the operation in US.

> > > > > >

> > > > > >

> > > > >

> > > >

> > >

> >

>

[Guest guest]

They also got a slice of my tumor.

Bindner

Web Directory (links to my sites and blogs):

http://www.geocities.com/mikeybdc/index.html

http://mikeybdc.blogspot.com

From: Francis Bill <georgewbill@...>Subject: Re: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Thursday, December 31, 2009, 2:42 PM

a nother study

Skip to Main Content

Home Search Study Topics Glossary

Full Text View

Tabular View

No Study Results Posted

Related Studies

Study of Adrenal Gland Tumors

This study is currently recruiting participants.

Verified by National Institutes of Health Clinical Center (CC), March 2009

First Received: June 28, 2000 Last Updated: November 25, 2009 History of Changes

Sponsor:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Information provided by:

National Institutes of Health Clinical Center (CC)

ClinicalTrials. gov Identifier:

NCT00005927

Purpose

The adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones. It is not known what causes these tumors or why some secrete hormones and others do not. Some of the tumors are benign and confined to the adrenal gland, and others are malignant (cancerous), and can spread to other parts of the body. This study will investigate how adrenal gland tumors develop, why some secrete steroid hormones and others do not, and why some are benign and others malignant.

Patients between 3 and 70 years old with a known or suspected adrenal gland tumor may be eligible for this study. Participants will be hospitalized for 7 to 10 days for various tests and procedures that may include the following:

Medical history and physical examination, including body measurements, as appropriate. Children and adolescents will have Tanner staging, including examination of the genitals, to determine the extent of sexual maturity.

24-hour urine collection to measure hormones in the urine.

Imaging studies, including magnetic resonance imaging (MRI) of the brain, computed tomography (CT) and other X-ray studies.

Blood tests to see if the tumor secretes hormones in response to specific stimuli, including exercise, food, and various hormones. The hormones are given through an intravenous catheter, or IV-a thin plastic tube inserted into an arm vein. After the stimulus, blood is drawn through the same IV every 30 minutes for up to 3 hours to measure hormone levels. Based on the results of these tests, some patients may have additional blood tests to check hormone response to special foods, an IV salt solution, or other hormones or drugs given either IV or by mouth (in pill form).

Photographs to document the effects on the body of abnormal hormone secretion from the adrenal tumor.

Small samples of blood and tumor tissue for research and DNA (genetic) analysis.

A discussion of treatment options will be based on the results of tests. If surgery to remove the tumor is recommended, the procedure can be done at NIH under this study protocol. If a malignant tumor is found that cannot be treated surgically, chemotherapy or radiation therapy may be recommended. These options are not offered under this protocol, but may be available under a different NIH study (for example, at the National Cancer Institute). Referrals will be made at the patient's request.

Patients who had surgery may be followed at the NIH outpatient clinic for 1 year after surgery. Patients with certain types of tumors may continue to be followed at NIH once a year for up to 5 years.

A registry of study participants will be created to keep records and correlate medical histories with tissues kept at NIH. The registry will also be used to inform participants of research studies they may be interested in. No individuals or organizations outside of NIH will have access to the registry.

Condition

Adrenal Gland Neoplasm

Study Type:

Observational

Official Title:

Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue

Resource links provided by NLM:

Genetics Home Reference related topics: Help Me Understand Genetics

MedlinePlus related topics: Adrenal Gland Cancer Cancer Surgery

Drug Information available for: Epinephrine bitartrate Epinephrine

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:

2000

Study Start Date:

June 2000Detailed Description:

The adrenal glands are the major source in the body of the steroid hormones. In normal physiology, the pituitary hormone ACTH regulates the secretion of glucocorticoids, while the secretion of mineralocorticoids is controlled by the renin-angiotensin system. In addition to these two steroids, the adrenal gland secretes lesser amounts of intermediate metabolites of these steroids, as well as the sex-steroids DHEA, DHEAS, androstenedione, testosterone, estrogen, and estrone. Dysregulated secretion of any of these hormones can be caused by sporadic adrenocortical adenomas or carcinomas, with the development of specific clinical syndromes depending on the identity of the hormones secreted. Similar clinical phenomena can also occur in the setting of a primary, bilateral hyperplasia of the adrenal cortex. In at least a subset of cortisol-producing adrenocortical neoplasms, the presence of ectopic or abnormal receptors has been described, resulting in the

regulation of cortisol by non-physiologic stimuli. The present study will serve as a mechanism to investigate individuals with steroid hormone-secreting adrenocortical tumors of all types for the purpose of identifying hereditary, congenital, or acquired defects leading not only to hormone oversecretion, but also to tumor formation. The first goal of the study will be to examine the prevalence of ectopic receptor expression in hormone secreting adrenocortical tumors. This aim will aid in the understanding of the ontogeny of these tumors, as well as lead to the development of novel therapeutic strategies (e.g., receptor antagonists) to control hormone oversecretion. The second goal of the study will be to perform a comparative analysis of the expression of large sets of genes using the emerging technology of gene array/gene chip analysis. This study will generate important diagnostic information about the malignant potential of adrenocortical neoplasms,

information which at present can only be obtained through follow-up of patients and retrospective analysis. This information may help to identify patients who would benefit from more aggressive intervention strategies. Thirdly, this study will also provide for the establishment of a bank of tissues of varying malignant potential from the adrenal cortex, which may serve in the future as an experimental resource to test new diagnostic and therapeutic methods.

Eligibility

Ages Eligible for Study:

3 Years to 70 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

INCLUSION CRITERIA:

Patients are adults or children with evidence for the existence of a tumor of the adrenal glands, as indicated by previously obtained imaging studies and/or biochemical investigation of hormonal secretion.

Patients must be willing to return to the NIH for follow-up evaluation..

Patients may withdraw from the study at any time.

For family members studied for linkage analysis, the following criteria must be met:

These individuals can be of any age. Each must be a member of a kindred suspected of having an inherited form of adrenal neoplasia, as evidenced by results of a patient studied under above eligibility criteria.

EXCLUSION CRITERIA:

Children less than 3 years old will be excluded.

Individuals over the age of 70 years of age will be excluded.

Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing or who have unacceptably high risk for surgical morbidity and mortality will be excluded.

Individuals found to have a known inherited syndrome as the cause for hormone oversecretion will be excluded.

Specific examples of syndromes to may be excluded from this protocol include individuals with Carney Complex, McCune-Albright syndrome, and MEN-1..

Individuals with a diagnosis of glucocorticoid- remediable aldosteronism (GRA) are excluded from participation in this protocol.

Contacts and Locations

Please refer to this study by its ClinicalTrials. gov identifier: NCT00005927

Contacts

Contact: Patient Recruitment and Public Liaison Office

(800) 411-1222

prpl@.... nih.gov

Contact: TTY

1-866-411-1010

Locations

United States, land

National Institutes of Health Clinical Center, 9000 Rockville Pike

Recruiting

Bethesda, land, United States, 20892

Sponsors and Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

More Information Additional Information: NIH Clinical Center Detailed Web Page Publications:

Dluhy RG, Lifton RP. Glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 1999 Dec;84(12):4341- 4. Review. No abstract available.

Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm. 1999;57:177- 216. Review.

Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998 Sep;83(9):3214- 8.

Study ID Numbers:

000160, 00-CH-0160

Study First Received:

June 28, 2000

Last Updated:

November 25, 2009

ClinicalTrials. gov Identifier:

NCT00005927 History of Changes

Health Authority:

United States: Federal GovernmentKeywords provided by National Institutes of Health Clinical Center (CC):

Adrenal AdenomaAdrenal CancerMacronodular AdrenalsEctopic ReceptorsGene ProfilingAdrenocortical Carcinoma

Cushing SyndromeVirilizing Adrenal TumorFeminizing Adrenal TumorMassive Macronodular Adrenocortical DiseaseAdrenal Gland TumorAdditional relevant MeSH terms:

NeoplasmsNeoplasms by SiteAdrenal Gland Neoplasms

Endocrine System DiseasesAdrenal Gland DiseasesEndocrine Gland NeoplasmsClinicalTrials. gov processed this record on December 30, 2009

Back to top of Main Content

Contact Help DeskLister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services,USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act Links to all studies - primarily for crawlers > > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for

AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>

[Guest guest]

They also got a slice of my tumor.

Bindner

Web Directory (links to my sites and blogs):

http://www.geocities.com/mikeybdc/index.html

http://mikeybdc.blogspot.com

From: Francis Bill <georgewbill@...>Subject: Re: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Thursday, December 31, 2009, 2:42 PM

a nother study

Skip to Main Content

Home Search Study Topics Glossary

Full Text View

Tabular View

No Study Results Posted

Related Studies

Study of Adrenal Gland Tumors

This study is currently recruiting participants.

Verified by National Institutes of Health Clinical Center (CC), March 2009

First Received: June 28, 2000 Last Updated: November 25, 2009 History of Changes

Sponsor:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Information provided by:

National Institutes of Health Clinical Center (CC)

ClinicalTrials. gov Identifier:

NCT00005927

Purpose

The adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones. It is not known what causes these tumors or why some secrete hormones and others do not. Some of the tumors are benign and confined to the adrenal gland, and others are malignant (cancerous), and can spread to other parts of the body. This study will investigate how adrenal gland tumors develop, why some secrete steroid hormones and others do not, and why some are benign and others malignant.

Patients between 3 and 70 years old with a known or suspected adrenal gland tumor may be eligible for this study. Participants will be hospitalized for 7 to 10 days for various tests and procedures that may include the following:

Medical history and physical examination, including body measurements, as appropriate. Children and adolescents will have Tanner staging, including examination of the genitals, to determine the extent of sexual maturity.

24-hour urine collection to measure hormones in the urine.

Imaging studies, including magnetic resonance imaging (MRI) of the brain, computed tomography (CT) and other X-ray studies.

Blood tests to see if the tumor secretes hormones in response to specific stimuli, including exercise, food, and various hormones. The hormones are given through an intravenous catheter, or IV-a thin plastic tube inserted into an arm vein. After the stimulus, blood is drawn through the same IV every 30 minutes for up to 3 hours to measure hormone levels. Based on the results of these tests, some patients may have additional blood tests to check hormone response to special foods, an IV salt solution, or other hormones or drugs given either IV or by mouth (in pill form).

Photographs to document the effects on the body of abnormal hormone secretion from the adrenal tumor.

Small samples of blood and tumor tissue for research and DNA (genetic) analysis.

A discussion of treatment options will be based on the results of tests. If surgery to remove the tumor is recommended, the procedure can be done at NIH under this study protocol. If a malignant tumor is found that cannot be treated surgically, chemotherapy or radiation therapy may be recommended. These options are not offered under this protocol, but may be available under a different NIH study (for example, at the National Cancer Institute). Referrals will be made at the patient's request.

Patients who had surgery may be followed at the NIH outpatient clinic for 1 year after surgery. Patients with certain types of tumors may continue to be followed at NIH once a year for up to 5 years.

A registry of study participants will be created to keep records and correlate medical histories with tissues kept at NIH. The registry will also be used to inform participants of research studies they may be interested in. No individuals or organizations outside of NIH will have access to the registry.

Condition

Adrenal Gland Neoplasm

Study Type:

Observational

Official Title:

Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue

Resource links provided by NLM:

Genetics Home Reference related topics: Help Me Understand Genetics

MedlinePlus related topics: Adrenal Gland Cancer Cancer Surgery

Drug Information available for: Epinephrine bitartrate Epinephrine

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:

2000

Study Start Date:

June 2000Detailed Description:

The adrenal glands are the major source in the body of the steroid hormones. In normal physiology, the pituitary hormone ACTH regulates the secretion of glucocorticoids, while the secretion of mineralocorticoids is controlled by the renin-angiotensin system. In addition to these two steroids, the adrenal gland secretes lesser amounts of intermediate metabolites of these steroids, as well as the sex-steroids DHEA, DHEAS, androstenedione, testosterone, estrogen, and estrone. Dysregulated secretion of any of these hormones can be caused by sporadic adrenocortical adenomas or carcinomas, with the development of specific clinical syndromes depending on the identity of the hormones secreted. Similar clinical phenomena can also occur in the setting of a primary, bilateral hyperplasia of the adrenal cortex. In at least a subset of cortisol-producing adrenocortical neoplasms, the presence of ectopic or abnormal receptors has been described, resulting in the

regulation of cortisol by non-physiologic stimuli. The present study will serve as a mechanism to investigate individuals with steroid hormone-secreting adrenocortical tumors of all types for the purpose of identifying hereditary, congenital, or acquired defects leading not only to hormone oversecretion, but also to tumor formation. The first goal of the study will be to examine the prevalence of ectopic receptor expression in hormone secreting adrenocortical tumors. This aim will aid in the understanding of the ontogeny of these tumors, as well as lead to the development of novel therapeutic strategies (e.g., receptor antagonists) to control hormone oversecretion. The second goal of the study will be to perform a comparative analysis of the expression of large sets of genes using the emerging technology of gene array/gene chip analysis. This study will generate important diagnostic information about the malignant potential of adrenocortical neoplasms,

information which at present can only be obtained through follow-up of patients and retrospective analysis. This information may help to identify patients who would benefit from more aggressive intervention strategies. Thirdly, this study will also provide for the establishment of a bank of tissues of varying malignant potential from the adrenal cortex, which may serve in the future as an experimental resource to test new diagnostic and therapeutic methods.

Eligibility

Ages Eligible for Study:

3 Years to 70 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

INCLUSION CRITERIA:

Patients are adults or children with evidence for the existence of a tumor of the adrenal glands, as indicated by previously obtained imaging studies and/or biochemical investigation of hormonal secretion.

Patients must be willing to return to the NIH for follow-up evaluation..

Patients may withdraw from the study at any time.

For family members studied for linkage analysis, the following criteria must be met:

These individuals can be of any age. Each must be a member of a kindred suspected of having an inherited form of adrenal neoplasia, as evidenced by results of a patient studied under above eligibility criteria.

EXCLUSION CRITERIA:

Children less than 3 years old will be excluded.

Individuals over the age of 70 years of age will be excluded.

Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing or who have unacceptably high risk for surgical morbidity and mortality will be excluded.

Individuals found to have a known inherited syndrome as the cause for hormone oversecretion will be excluded.

Specific examples of syndromes to may be excluded from this protocol include individuals with Carney Complex, McCune-Albright syndrome, and MEN-1..

Individuals with a diagnosis of glucocorticoid- remediable aldosteronism (GRA) are excluded from participation in this protocol.

Contacts and Locations

Please refer to this study by its ClinicalTrials. gov identifier: NCT00005927

Contacts

Contact: Patient Recruitment and Public Liaison Office

(800) 411-1222

prpl@.... nih.gov

Contact: TTY

1-866-411-1010

Locations

United States, land

National Institutes of Health Clinical Center, 9000 Rockville Pike

Recruiting

Bethesda, land, United States, 20892

Sponsors and Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

More Information Additional Information: NIH Clinical Center Detailed Web Page Publications:

Dluhy RG, Lifton RP. Glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 1999 Dec;84(12):4341- 4. Review. No abstract available.

Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm. 1999;57:177- 216. Review.

Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998 Sep;83(9):3214- 8.

Study ID Numbers:

000160, 00-CH-0160

Study First Received:

June 28, 2000

Last Updated:

November 25, 2009

ClinicalTrials. gov Identifier:

NCT00005927 History of Changes

Health Authority:

United States: Federal GovernmentKeywords provided by National Institutes of Health Clinical Center (CC):

Adrenal AdenomaAdrenal CancerMacronodular AdrenalsEctopic ReceptorsGene ProfilingAdrenocortical Carcinoma

Cushing SyndromeVirilizing Adrenal TumorFeminizing Adrenal TumorMassive Macronodular Adrenocortical DiseaseAdrenal Gland TumorAdditional relevant MeSH terms:

NeoplasmsNeoplasms by SiteAdrenal Gland Neoplasms

Endocrine System DiseasesAdrenal Gland DiseasesEndocrine Gland NeoplasmsClinicalTrials. gov processed this record on December 30, 2009

Back to top of Main Content

Contact Help DeskLister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services,USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act Links to all studies - primarily for crawlers > > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for

AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>

[Guest guest]

Make sure he or she does it.

Bindner

Web Directory (links to my sites and blogs):

http://www.geocities.com/mikeybdc/index.html

http://mikeybdc.blogspot.com

From: <bryanfjohnson@...>Subject: Re: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Thursday, December 31, 2009, 2:48 PM

Thanks Mike.Just called. They need my Endo to give the Study Coordinator a call.> > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >>

>>

[Guest guest]

Good you can also say I referred you. CE Grim MDOn Dec 31, 2009, at 1:48 PM, wrote:Thanks Mike.Just called. They need my Endo to give the Study Coordinator a call.> > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>

[Guest guest]

Good you can also say I referred you. CE Grim MDOn Dec 31, 2009, at 1:48 PM, wrote:Thanks Mike.Just called. They need my Endo to give the Study Coordinator a call.> > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>

[Guest guest]

Good contribution. Only way we learn.Do you get any feedback on that?Ask for copies of any papers that use your adrenal contribution.CE GrimOn Dec 31, 2009, at 2:33 PM, Bindner wrote:They also got a slice of my tumor. Bindner Web Directory (links to my sites and blogs):http://www.geocities.com/mikeybdc/index.htmlhttp://mikeybdc.blogspot.com --- On Thu, 12/31/09, Francis Bill <georgewbill > wrote:From: Francis Bill <georgewbill >Subject: Re: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Thursday, December 31, 2009, 2:42 PM a nother study Skip to Main ContentHome Search Study Topics Glossary Full Text ViewTabular ViewNo Study Results PostedRelated StudiesStudy of Adrenal Gland TumorsThis study is currently recruiting participants.Verified by National Institutes of Health Clinical Center (CC), March 2009First Received: June 28, 2000 Last Updated: November 25, 2009 History of ChangesSponsor:Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Information provided by:National Institutes of Health Clinical Center (CC)ClinicalTrials. gov Identifier:NCT00005927 PurposeThe adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones. It is not known what causes these tumors or why some secrete hormones and others do not. Some of the tumors are benign and confined to the adrenal gland, and others are malignant (cancerous), and can spread to other parts of the body. This study will investigate how adrenal gland tumors develop, why some secrete steroid hormones and others do not, and why some are benign and others malignant.Patients between 3 and 70 years old with a known or suspected adrenal gland tumor may be eligible for this study. Participants will be hospitalized for 7 to 10 days for various tests and procedures that may include the following:Medical history and physical examination, including body measurements, as appropriate. Children and adolescents will have Tanner staging, including examination of the genitals, to determine the extent of sexual maturity.24-hour urine collection to measure hormones in the urine.Imaging studies, including magnetic resonance imaging (MRI) of the brain, computed tomography (CT) and other X-ray studies.Blood tests to see if the tumor secretes hormones in response to specific stimuli, including exercise, food, and various hormones. The hormones are given through an intravenous catheter, or IV-a thin plastic tube inserted into an arm vein. After the stimulus, blood is drawn through the same IV every 30 minutes for up to 3 hours to measure hormone levels. Based on the results of these tests, some patients may have additional blood tests to check hormone response to special foods, an IV salt solution, or other hormones or drugs given either IV or by mouth (in pill form).Photographs to document the effects on the body of abnormal hormone secretion from the adrenal tumor.Small samples of blood and tumor tissue for research and DNA (genetic) analysis.A discussion of treatment options will be based on the results of tests. If surgery to remove the tumor is recommended, the procedure can be done at NIH under this study protocol. If a malignant tumor is found that cannot be treated surgically, chemotherapy or radiation therapy may be recommended. These options are not offered under this protocol, but may be available under a different NIH study (for example, at the National Cancer Institute). Referrals will be made at the patient's request.Patients who had surgery may be followed at the NIH outpatient clinic for 1 year after surgery. Patients with certain types of tumors may continue to be followed at NIH once a year for up to 5 years.A registry of study participants will be created to keep records and correlate medical histories with tissues kept at NIH. The registry will also be used to inform participants of research studies they may be interested in. No individuals or organizations outside of NIH will have access to the registry.ConditionAdrenal Gland NeoplasmStudy Type:ObservationalOfficial Title:Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical TissueResource links provided by NLM:Genetics Home Reference related topics: Help Me Understand GeneticsMedlinePlus related topics: Adrenal Gland Cancer Cancer SurgeryDrug Information available for: Epinephrine bitartrate EpinephrineU.S. FDA ResourcesFurther study details as provided by National Institutes of Health Clinical Center (CC):Estimated Enrollment:2000Study Start Date:June 2000Detailed Description:The adrenal glands are the major source in the body of the steroid hormones. In normal physiology, the pituitary hormone ACTH regulates the secretion of glucocorticoids, while the secretion of mineralocorticoids is controlled by the renin-angiotensin system. In addition to these two steroids, the adrenal gland secretes lesser amounts of intermediate metabolites of these steroids, as well as the sex-steroids DHEA, DHEAS, androstenedione, testosterone, estrogen, and estrone. Dysregulated secretion of any of these hormones can be caused by sporadic adrenocortical adenomas or carcinomas, with the development of specific clinical syndromes depending on the identity of the hormones secreted. Similar clinical phenomena can also occur in the setting of a primary, bilateral hyperplasia of the adrenal cortex. In at least a subset of cortisol-producing adrenocortical neoplasms, the presence of ectopic or abnormal receptors has been described, resulting in the regulation of cortisol by non-physiologic stimuli. The present study will serve as a mechanism to investigate individuals with steroid hormone-secreting adrenocortical tumors of all types for the purpose of identifying hereditary, congenital, or acquired defects leading not only to hormone oversecretion, but also to tumor formation. The first goal of the study will be to examine the prevalence of ectopic receptor expression in hormone secreting adrenocortical tumors. This aim will aid in the understanding of the ontogeny of these tumors, as well as lead to the development of novel therapeutic strategies (e.g., receptor antagonists) to control hormone oversecretion. The second goal of the study will be to perform a comparative analysis of the expression of large sets of genes using the emerging technology of gene array/gene chip analysis. This study will generate important diagnostic information about the malignant potential of adrenocortical neoplasms, information which at present can only be obtained through follow-up of patients and retrospective analysis. This information may help to identify patients who would benefit from more aggressive intervention strategies. Thirdly, this study will also provide for the establishment of a bank of tissues of varying malignant potential from the adrenal cortex, which may serve in the future as an experimental resource to test new diagnostic and therapeutic methods. EligibilityAges Eligible for Study: 3 Years to 70 YearsGenders Eligible for Study: BothAccepts Healthy Volunteers: NoCriteriaINCLUSION CRITERIA:Patients are adults or children with evidence for the existence of a tumor of the adrenal glands, as indicated by previously obtained imaging studies and/or biochemical investigation of hormonal secretion.Patients must be willing to return to the NIH for follow-up evaluation..Patients may withdraw from the study at any time.For family members studied for linkage analysis, the following criteria must be met:These individuals can be of any age. Each must be a member of a kindred suspected of having an inherited form of adrenal neoplasia, as evidenced by results of a patient studied under above eligibility criteria.EXCLUSION CRITERIA:Children less than 3 years old will be excluded.Individuals over the age of 70 years of age will be excluded.Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing or who have unacceptably high risk for surgical morbidity and mortality will be excluded.Individuals found to have a known inherited syndrome as the cause for hormone oversecretion will be excluded.Specific examples of syndromes to may be excluded from this protocol include individuals with Carney Complex, McCune-Albright syndrome, and MEN-1..Individuals with a diagnosis of glucocorticoid- remediable aldosteronism (GRA) are excluded from participation in this protocol. Contacts and LocationsPlease refer to this study by its ClinicalTrials. gov identifier: NCT00005927ContactsContact: Patient Recruitment and Public Liaison Office(800) 411-1222prpl@.... nih.govContact: TTY1-866-411-1010LocationsUnited States, landNational Institutes of Health Clinical Center, 9000 Rockville PikeRecruitingBethesda, land, United States, 20892Sponsors and CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) More InformationAdditional Information:NIH Clinical Center Detailed Web Page Publications:Dluhy RG, Lifton RP. Glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 1999 Dec;84(12):4341- 4. Review. No abstract available.Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm. 1999;57:177- 216. Review.Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998 Sep;83(9):3214- 8.Study ID Numbers:000160, 00-CH-0160Study First Received:June 28, 2000Last Updated:November 25, 2009ClinicalTrials. gov Identifier:NCT00005927 History of ChangesHealth Authority:United States: Federal GovernmentKeywords provided by National Institutes of Health Clinical Center (CC):Adrenal AdenomaAdrenal CancerMacronodular AdrenalsEctopic ReceptorsGene ProfilingAdrenocortical CarcinomaCushing SyndromeVirilizing Adrenal TumorFeminizing Adrenal TumorMassive Macronodular Adrenocortical DiseaseAdrenal Gland TumorAdditional relevant MeSH terms:NeoplasmsNeoplasms by SiteAdrenal Gland NeoplasmsEndocrine System DiseasesAdrenal Gland DiseasesEndocrine Gland NeoplasmsClinicalTrials. gov processed this record on December 30, 2009Back to top of Main ContentContact Help DeskLister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services,USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act Links to all studies - primarily for crawlers> > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>

[Guest guest]

Good contribution. Only way we learn.Do you get any feedback on that?Ask for copies of any papers that use your adrenal contribution.CE GrimOn Dec 31, 2009, at 2:33 PM, Bindner wrote:They also got a slice of my tumor. Bindner Web Directory (links to my sites and blogs):http://www.geocities.com/mikeybdc/index.htmlhttp://mikeybdc.blogspot.com --- On Thu, 12/31/09, Francis Bill <georgewbill > wrote:From: Francis Bill <georgewbill >Subject: Re: AVS and Laparoscopic Adrenalectomy Costhyperaldosteronism Date: Thursday, December 31, 2009, 2:42 PM a nother study Skip to Main ContentHome Search Study Topics Glossary Full Text ViewTabular ViewNo Study Results PostedRelated StudiesStudy of Adrenal Gland TumorsThis study is currently recruiting participants.Verified by National Institutes of Health Clinical Center (CC), March 2009First Received: June 28, 2000 Last Updated: November 25, 2009 History of ChangesSponsor:Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Information provided by:National Institutes of Health Clinical Center (CC)ClinicalTrials. gov Identifier:NCT00005927 PurposeThe adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones. It is not known what causes these tumors or why some secrete hormones and others do not. Some of the tumors are benign and confined to the adrenal gland, and others are malignant (cancerous), and can spread to other parts of the body. This study will investigate how adrenal gland tumors develop, why some secrete steroid hormones and others do not, and why some are benign and others malignant.Patients between 3 and 70 years old with a known or suspected adrenal gland tumor may be eligible for this study. Participants will be hospitalized for 7 to 10 days for various tests and procedures that may include the following:Medical history and physical examination, including body measurements, as appropriate. Children and adolescents will have Tanner staging, including examination of the genitals, to determine the extent of sexual maturity.24-hour urine collection to measure hormones in the urine.Imaging studies, including magnetic resonance imaging (MRI) of the brain, computed tomography (CT) and other X-ray studies.Blood tests to see if the tumor secretes hormones in response to specific stimuli, including exercise, food, and various hormones. The hormones are given through an intravenous catheter, or IV-a thin plastic tube inserted into an arm vein. After the stimulus, blood is drawn through the same IV every 30 minutes for up to 3 hours to measure hormone levels. Based on the results of these tests, some patients may have additional blood tests to check hormone response to special foods, an IV salt solution, or other hormones or drugs given either IV or by mouth (in pill form).Photographs to document the effects on the body of abnormal hormone secretion from the adrenal tumor.Small samples of blood and tumor tissue for research and DNA (genetic) analysis.A discussion of treatment options will be based on the results of tests. If surgery to remove the tumor is recommended, the procedure can be done at NIH under this study protocol. If a malignant tumor is found that cannot be treated surgically, chemotherapy or radiation therapy may be recommended. These options are not offered under this protocol, but may be available under a different NIH study (for example, at the National Cancer Institute). Referrals will be made at the patient's request.Patients who had surgery may be followed at the NIH outpatient clinic for 1 year after surgery. Patients with certain types of tumors may continue to be followed at NIH once a year for up to 5 years.A registry of study participants will be created to keep records and correlate medical histories with tissues kept at NIH. The registry will also be used to inform participants of research studies they may be interested in. No individuals or organizations outside of NIH will have access to the registry.ConditionAdrenal Gland NeoplasmStudy Type:ObservationalOfficial Title:Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical TissueResource links provided by NLM:Genetics Home Reference related topics: Help Me Understand GeneticsMedlinePlus related topics: Adrenal Gland Cancer Cancer SurgeryDrug Information available for: Epinephrine bitartrate EpinephrineU.S. FDA ResourcesFurther study details as provided by National Institutes of Health Clinical Center (CC):Estimated Enrollment:2000Study Start Date:June 2000Detailed Description:The adrenal glands are the major source in the body of the steroid hormones. In normal physiology, the pituitary hormone ACTH regulates the secretion of glucocorticoids, while the secretion of mineralocorticoids is controlled by the renin-angiotensin system. In addition to these two steroids, the adrenal gland secretes lesser amounts of intermediate metabolites of these steroids, as well as the sex-steroids DHEA, DHEAS, androstenedione, testosterone, estrogen, and estrone. Dysregulated secretion of any of these hormones can be caused by sporadic adrenocortical adenomas or carcinomas, with the development of specific clinical syndromes depending on the identity of the hormones secreted. Similar clinical phenomena can also occur in the setting of a primary, bilateral hyperplasia of the adrenal cortex. In at least a subset of cortisol-producing adrenocortical neoplasms, the presence of ectopic or abnormal receptors has been described, resulting in the regulation of cortisol by non-physiologic stimuli. The present study will serve as a mechanism to investigate individuals with steroid hormone-secreting adrenocortical tumors of all types for the purpose of identifying hereditary, congenital, or acquired defects leading not only to hormone oversecretion, but also to tumor formation. The first goal of the study will be to examine the prevalence of ectopic receptor expression in hormone secreting adrenocortical tumors. This aim will aid in the understanding of the ontogeny of these tumors, as well as lead to the development of novel therapeutic strategies (e.g., receptor antagonists) to control hormone oversecretion. The second goal of the study will be to perform a comparative analysis of the expression of large sets of genes using the emerging technology of gene array/gene chip analysis. This study will generate important diagnostic information about the malignant potential of adrenocortical neoplasms, information which at present can only be obtained through follow-up of patients and retrospective analysis. This information may help to identify patients who would benefit from more aggressive intervention strategies. Thirdly, this study will also provide for the establishment of a bank of tissues of varying malignant potential from the adrenal cortex, which may serve in the future as an experimental resource to test new diagnostic and therapeutic methods. EligibilityAges Eligible for Study: 3 Years to 70 YearsGenders Eligible for Study: BothAccepts Healthy Volunteers: NoCriteriaINCLUSION CRITERIA:Patients are adults or children with evidence for the existence of a tumor of the adrenal glands, as indicated by previously obtained imaging studies and/or biochemical investigation of hormonal secretion.Patients must be willing to return to the NIH for follow-up evaluation..Patients may withdraw from the study at any time.For family members studied for linkage analysis, the following criteria must be met:These individuals can be of any age. Each must be a member of a kindred suspected of having an inherited form of adrenal neoplasia, as evidenced by results of a patient studied under above eligibility criteria.EXCLUSION CRITERIA:Children less than 3 years old will be excluded.Individuals over the age of 70 years of age will be excluded.Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing or who have unacceptably high risk for surgical morbidity and mortality will be excluded.Individuals found to have a known inherited syndrome as the cause for hormone oversecretion will be excluded.Specific examples of syndromes to may be excluded from this protocol include individuals with Carney Complex, McCune-Albright syndrome, and MEN-1..Individuals with a diagnosis of glucocorticoid- remediable aldosteronism (GRA) are excluded from participation in this protocol. Contacts and LocationsPlease refer to this study by its ClinicalTrials. gov identifier: NCT00005927ContactsContact: Patient Recruitment and Public Liaison Office(800) 411-1222prpl@.... nih.govContact: TTY1-866-411-1010LocationsUnited States, landNational Institutes of Health Clinical Center, 9000 Rockville PikeRecruitingBethesda, land, United States, 20892Sponsors and CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) More InformationAdditional Information:NIH Clinical Center Detailed Web Page Publications:Dluhy RG, Lifton RP. Glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 1999 Dec;84(12):4341- 4. Review. No abstract available.Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm. 1999;57:177- 216. Review.Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998 Sep;83(9):3214- 8.Study ID Numbers:000160, 00-CH-0160Study First Received:June 28, 2000Last Updated:November 25, 2009ClinicalTrials. gov Identifier:NCT00005927 History of ChangesHealth Authority:United States: Federal GovernmentKeywords provided by National Institutes of Health Clinical Center (CC):Adrenal AdenomaAdrenal CancerMacronodular AdrenalsEctopic ReceptorsGene ProfilingAdrenocortical CarcinomaCushing SyndromeVirilizing Adrenal TumorFeminizing Adrenal TumorMassive Macronodular Adrenocortical DiseaseAdrenal Gland TumorAdditional relevant MeSH terms:NeoplasmsNeoplasms by SiteAdrenal Gland NeoplasmsEndocrine System DiseasesAdrenal Gland DiseasesEndocrine Gland NeoplasmsClinicalTrials. gov processed this record on December 30, 2009Back to top of Main ContentContact Help DeskLister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services,USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act Links to all studies - primarily for crawlers> > > > > > > > > > > Hi,> > > > > >> > > > > > What is the typical cost for AVS and the Laparoscopic Adrenalectomy?> > > > > >> > > > > > I am considering doing the operation in US.> > > > > >> > > > > >> > > > >> > > >> > >> >>